Use the hyperlinks, where available to access additional clinical trial information.
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Eli Lilly and Company
Eligible participants will be randomly allocated to one of three treatment arms. In Arm 1 (Experimental), participants will receive Imlunestrant alone, administered orally. In Arm 2 (Active Comparator), participants will receive the investigator's choice of either Exemestane (administered orally) or Fulvestrant (administered intramuscularly). In Arm 3 (Experimental), participants will receive Imlunestrant plus Abemaciclib, both administered orally.